Answers are grounded in this paper and cite their sources.
Purpose: Effective second-line fertility-preserving treatment for progestin-insensitive endometrial atypical hyperplasia (EAH) has not been established. We compare the efficacy and safety of gonadotropin-releasing hormone agonist (GnRH-a) plus letrozole with ethinylestradiol/cyproterone acetate (Diane-35) plus metformin in this population. Patients and Methods: In this multicenter, open-label, randomized phase II trial, patients aged 18–45 years with progestin-insensitive EAH seeking fertility preservation were assigned 1:1 to GnRH-a plus letrozole or Diane-35 plus metformin. Treatment response was assessed by scheduled hysteroscopy with pathological evaluation. The primary endpoint was the complete response (CR) rate within 28 weeks after second-line treatment initiation. Secondary endpoints reported in this analysis included time to CR, adverse events and compliance. Results: From July 2022 to July 2025, 41 patients were randomized and analyzed by intention-to-treat analysis. CR within 28 weeks was achieved in 19 of 20 patients (95.0%) in the GnRH-a plus letrozole group and 14 of 21 patients (66.7%) in the Diane-35 plus metformin group, corresponding to a risk difference of 28.3 percentage points (95% CI, 3.7–50.0; two-sided Fisher’s exact P=0.045). Median time to CR was shorter in the GnRH-a plus letrozole group than in the Diane-35 plus metformin group (12.86 weeks vs. 17.29 weeks, HR, 2.12; 95% CI, 1.05–4.28; log-rank P=0.029). No grade 4 adverse events or thromboembolic events occurred. Conclusions: GnRH-a plus letrozole was associated with a higher 28-week CR rate and shorter time to CR than Diane-35 plus metformin after initiation of second-line treatment for progestin-insensitive EAH, with acceptable short-term safety.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: